ICON plc has acquired MolecularMD, a molecular diagnostic specialty laboratory focused on the development and commercialization of precision medicines in oncology.    The acquisition enhances ICON’s laboratory offering in molecular diagnostic testing and brings to ICON expanded testing platforms, including next generation sequencing, and immunohistochemistry (IHC). “We are delighted to be joining ICON,” said Dan Snyder, president, MolecularMD. “Together with ICON, we can offer clients br...